ATLANTA -- Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback